MRNS Marinus Pharma: רווח למניה ב-12 החודשים האחרונים

The high market protection of Marinus Pharmaceuticals (MRNS) is based on FDA patents and the complexity of neurosteroid synthesis. On GURU.Markets, the trend of the rolling annual EPS YoY captures this success, where -517.70 reflects the latest value of the metric. Business resilience is bolstered by the testing of drugs against various forms of epilepsy, while the environmental focus is implemented through the introduction of "green chemistry" methods in laboratories.
MRNS (Marinus): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The expansion of Ztalmy and the development of the neuropharmacological pipeline at Marinus Pharmaceuticals (MRNS) directly impact profit dynamics. The measurement of annual EPS TTM growth captures the percentage change in net income per share over the last twelve months. This metric reflects cost management efficiency and the business's ability to generate real income. Analyzing the curve allows for the timely identification of trend reversals in efficiency. Stable growth of this indicator confirms the fundamental resilience of the asset.